Clinical Trial Update: EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma [Phase 1]

View source ↗

Summary

Phase 1 trial update for EGFRvIII CAR T cells in newly diagnosed high-grade glioma (glioblastoma/gliosarcoma) has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• EGFRvIII CAR T cells (EGFRvIII-targeted CAR T cells)

Snippet

Sponsor: Daniel Landi | Conditions: Glioblastoma, Gliosarcoma | Phase 1 | Status: TERMINATED | Results posted: 2020-07-24